natgillin/translations-raw huggingface dataset:
Ved gentagen oral dosering af 700 mg fosamprenavir og 100 mg ritonavir 2 gange daglig blev amprenavir hurtigt absorberet med en maksimal steady state amprenavir-plasmakoncentration (Cmax) på 6,08 (5,38-6,86) g/ml (geometrisk gennemsnit (95 % CI)) ca. 1,5 (0,75-5,0) timer efter dosering (tmax). 
After multiple dose oral administration of fosamprenavir 700 mg with ritonavir 100 mg twice daily, amprenavir was rapidly absorbed with a geometric mean (95 % CI) steady state peak plasma amprenavir concentration (Cmax) of 6.08 (5.38-6.86) µg/ml occurring approximately 1.5 (0.75-5.0) hours after dosing (tmax).
Amprenavirs distribution til cerebrospinalvæsken er ubetydelig hos mennesker. 
CSF penetration of amprenavir is negligible in humans.
Baseline-hiv-1-RNA ≥ 100.000 kopier/ml 
Baseline HIV-1 RNA ≥ 100,000 copies/ml
• Øvrige indholdsstoffer: mikrokrystallinsk cellulose, croscarmellosenatrium, povidon K30, magnesiumstearat, kolloid vandfri silica, hypromellose, titandioxid (E171), glyceroltriacetat, rød jernoxid (E172). 
magnesium stearate, colloidal anhydrous silica, hypromellose, titanium dioxide (E171), glycerol triacetate, iron oxide red (E172).
Fosamprenavir og ritonavir bør seponeres permanent i tilfælde af alvorlige udslæt, eller i tilfælde af milde eller moderate udslæt ledsaget af systemiske eller mucosale symptomer (se pkt. 
Fosamprenavir with ritonavir therapy should be definitively stopped in case of severe rash or in case of rash of mild or moderate intensity associated with systemic or mucosal signs (see section 4.4).
ORALE ANTIKOAGULANTIA 
ORAL ANTICOAGULANTS
Resultater fra studier med andre hiv-proteasehæmmere og simeprevir eller daclatasvir antyder, at administration sammen med fosamprenavir/ritonavir sandsynligvis medfører øget plasmaniveau af simeprevir og daclatasvir pga. CYP3A4enzymhæmning. 
Results from studies with other HIV protease inhibitors and simeprevir or daclatasvir, suggest that coadministration with fosamprenavir/ritonavir is likely to lead to increased plasma exposures of simeprevir or daclatasvir due to CYP3A4 enzyme inhibition.
Cmax 14 % (-36 % til +15 %) AUC 16 % (-36 % til +8 %) Cmin 19 % (-42 % til +13 %) 
AUC ↓ 16% (-36%; +8%) Cmin ↓ 19% (-42%; +13%)
Den voksne dosering, en Telzir tablet på 700 mg i kombination med 100 mg ritonavir 2 gange daglig, kan anvendes til børn, hvis de vejer mindst 39 kg og kan sluge tabletter. 
The adult dose of Telzir tablet 700 mg twice daily with ritonavir 100 mg twice daily may be used in children weighing at least 39 kg and able to swallow tablets.
> 100,000 kopier/ml, n (%) median CD4 celler/μl CD4-tal < 350 celler/μl, n (%) Effektresultat 
Median CD4 cells/μl CD4 count < 350 cells/μl, n (%)
FPV/RTV 2 gange daglig (n=107) 
FPV/RTV BID (N=107)
Etravirin Cmax  
Norethisterone: Cmax
4.3 og 4.5). 
Results from studies with 4.3).
• hvis du er allergisk over for medicin, der indeholder sulfonamid, da du så også kan være allergisk over for Telzir 
• If you have a known allergy to medicines containing sulphonamide.
Den induktive effekt kan vare i op til 2 uger efter seponering af perikon. 
The inducing effect may persist for at least 2 weeks after cessation of treatment with St John's wort.
Vend flasken på hovedet. 
Turn the bottle upside down.
Telzir må kun administreres i kombination med en lav dosis ritonavir og i kombination med andre antiretrovirale lægemidler. 
Telzir must only be given with low dose ritonavir as a pharmacokinetic enhancer of amprenavir and in combination with other antiretroviral medicinal products.
Antibiotika: 
INFECTION Antibacterials:
Varigheden (median) af sidste behandling med proteasehæmmere var 149 uger for patienter, som fik fosamprenavir og ritonavir 2 gange daglig (49 % havde tidligere fået  2 PI'er), og 130 uger for patienter, som fik lopinavir/ritonavir (40 % havde tidligere fået  2 PI'er). 
The median durations of prior exposure to protease inhibitors were 149 weeks for patients receiving fosamprenavir with ritonavir twice daily (49 % received ≥ 2 prior PIs) and 130 weeks for patients receiving lopinavir/ritonavir (40 % received ≥2 prior PIs).
Hos rotteunger, der før og efter fødslen har været eksponeret for amprenavir og fosamprenavir, blev der observeret tegn på udviklingstoksicitet (se pkt. 
Rat pups exposed pre and post-natally to amprenavir and fosamprenavir showed developmental toxicity (see section 5.3).
Lurasidon:  forventet (CYP3A4 hæmning) 
Lurasidone: ↑ expected (CYP3A4 inhibition)
Hæmofilipatienter: Der er rapporteret om øget spontan blødningstendens hos hæmofilipatienter, som blev behandlet med proteasehæmmere (se pkt. 
Haemophiliac patients: There have been reports of increased spontaneous bleeding in haemophiliac patients receiving antiretroviral protease inhibitors (see section 4.4).
Rabdomyolyse: Der er i forbindelse med proteasehæmmere rapporteret om forhøjet CPK, myalgi og myositis. 
Rhabdomyolysis: an increase in CPK, myalgia, myositis, and rarely, rhabdomyolysis, have been reported with protease inhibitors, more specifically in association with nucleoside analogues.
I langtidskarcinogenicitetsstudier af fosamprenavir sås stigninger i hepatocellulære adenomaer og hepatocellulære carcinomaer hos mus ved eksponeringsniveauer 0,1-0,3 gange større end den humane dosis på 700 mg fosamprenavir plus 100 mg ritonavir 2 gange daglig. 
In long-term carcinogenicity studies with fosamprenavir in mice and rats, there were increases in hepatocellular adenomas and hepatocellular carcinomas in mice at exposure levels equivalent to 0.1 to 0.3-fold those in humans given 700 mg of fosamprenavir plus 100 mg ritonavir twice daily, and increases in hepatocellular adenomas and thyroid follicular cell adenomas in rats at exposure levels equivalent to 0.3 to 0.6-fold those in humans given 700 mg of fosamprenavir plus 100 mg ritonavir twice daily.
Amprenavir:  forventet (Beskeden CYP3A4-induktion) 
Amprenavir: ↓ expected (Modest CYP3A4 induction)
Udslæt (se nedenfor under ”Udslæt/hudreaktioner”) Angioødem 
Rash (see text below “rash/cutaneous reactions”)
Spørg lægen eller apotekspersonalet, hvis du har spørgsmål om ritonavir eller anden medicin. 
If you have any further questions about ritonavir or the other medicines prescribed, please ask your doctor or pharmacist.
• stigning i mængden af leverenzymer (transaminaser) og pancreasenzym (lipase) 
• Increases in enzymes produced by the liver called transaminases, increases of an enzyme produced by the pancreas called lipase.
Filmovertrukne tabletter Glaxo Wellcome Operations, Priory Street, Ware, Hertfordshire SG12 0DJ, Storbritannien. 
Glaxo Wellcome Operations, Priory Street, Ware, Hertfordshire SG12 0DJ, United Kingdom Glaxo Wellcome S.A., Avenida de Extremadura 3, 09400 Aranda de Duero Burgos, Spain Oral suspension
Overfølsomhed over for fosamprenavir, amprenavir, ritonavir eller over for et eller flere af hjælpestofferne anført i pkt. 
Hypersensitivity to fosamprenavir, amprenavir, or ritonavir, or to any of the excipients listed in section
Du kan få udslæt, men du kan blive ved med at tage Telzir. 
However you can still continue to take Telzir.
Nevirapin 200 mg 2 gange daglig 
Nevirapine 200 mg twice daily
Den anbefalede dosis er 700 mg fosamprenavir 2 gange daglig i kombination med 100 mg ritonavir 2 gange daglig. 
The recommended dose is 700 mg fosamprenavir twice daily with 100 mg ritonavir twice daily.
Tabletterne er præget `GXLL7´ på den ene side. 
The tablets are capsule shaped, biconvex, pink coloured and marked with ‘GXLL7' on one side.
Methylparahydroxybenzoat (E218) Propylparahydroxybenzoat (E216) Polysorbat 80 
Methyl parahydroxybenzoate (E218) Propyl parahydroxybenzoate (E216) Polysorbate 80
• atorvastatin doser på mere end 20 mg om dagen (mod forhøjet kolesterol i blodet) 
• doses of atorvastatin greater than 20 mg per day (used to lower cholesterol)
I et randomiseret åbent studie (ESS100732 - KLEAN) hos antiretroviral-naive patienter, viste fosamprenavir (700 mg) med samtidig administration med en lavdosis ritonavir (100 mg) 2 gange daglig og en fast-dosis kombinationstablet af abacavir/lamivudin (600 mg/300 mg) én gang daglig, at have sammenlignelig effekt over 48 uger med lopinavir/ritonavir (400 mg/100 mg) givet 2 gange daglig i kombination med abacavir/lamivudin (600 mg/300 mg én gang daglig). 
In a randomised open-label study (ESS100732 - KLEAN) in antiretroviral naïve patients, fosamprenavir (700 mg) co-administered with low dose ritonavir (100 mg) in a twice daily regimen including abacavir / lamivudine (600 mg / 300 mg) fixed dose combination tablet once daily showed comparable efficacy over 48 weeks to lopinavir / ritonavir (400 mg / 100 mg) given twice daily in combination with abacavir / lamivudine (600 mg / 300 mg once daily).
Til voksne med svært nedsat leverfunktion (Child-Pugh Score: 10-15) bør fosamprenavir anvendes med forsigtighed og i reduceret dosis på 300 mg fosamprenavir 2 gange daglig i kombination med 100 mg ritonavir en gang daglig. 
For adults with severe hepatic impairment (Child-Pugh score: 10-15): fosamprenavir should be used with caution and at a reduced dose of 300 mg fosamprenavir twice daily with 100 mg ritonavir once daily.
(Kombineret CYP3A4induktion/hæmning, Pglykoprotein-induktion) 
(Mixed CYP3A4 induction/inhibition, Pgp induction)
Ikke-fastende 
Not recommended
FPV/RTV 2 gange daglig vs LPV/RTV 2 gange daglig 
FPV/RTV BID - Fosamprenavir with ritonavir twice daily, LPV/RTV BID - Lopinavir / ritonavir twice daily
Lægemidler - interaktioner Brugen af Telzir sammen med halofantrin eller lidocain (systemisk) kan ikke anbefales (se pkt. 
The use of Telzir concomitantly with halofantrine or lidocaine (systemic) is not recommended (see section 4.5).
Ætiologien anses dog for at være multifaktoriel (omfattende anvendelse af kortikosteroider, alkoholforbrug, svær immunsuppression, højere Body Mass Index (BMI)). 
Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to CART.
Når Telzir tabletter og oral suspension blev administreret ved faste var plasma amprenavir AUC værdierne for de to formuleringer ækvivalente. 
Telzir tablet and oral suspension formulations, both given fasted, delivered equivalent plasma amprenavir AUC∞ values and the Telzir oral suspension formulation delivered a 14 % higher plasma amprenavir Cmax as compared to the oral tablet formulation.
Voksne bør derfor tage Telzir oral suspension uden mad og på tom mave (se pkt. 
Therefore for adult patients the Telzir oral suspension should be taken without food and on an empty stomach (see section 4.2).
Lopinavir: Cmax * Lopinavir: AUC * Lopinavir: Cmin * * sammenlignet med lopinavir / ritonavir 400 mg/100 mg 2 gange daglig 
Lopinavir: Cmax ↔* Lopinavir: AUC ↔* Lopinavir: Cmin ↔* * compared to lopinavir / ritonavir 400 mg/100 mg twice daily
På trods af den reducerede doseringshyppighed af ritonavir havde personer med svært nedsat leverfunktion en 64 % højere plasma-Cmax, 40 % højere plasma-AUC(0-24) og 38 % højere plasma-C12-værdier for ritonavir i forhold til patienter med normal leverfunktion, der fik standardbehandlingen 700 mg fosamprenavir i kombination med 100 mg ritonavir 2 gange daglig. 
Despite reducing the dosing frequency of ritonavir, subjects with severe hepatic impairment had 64% higher ritonavir Cmax, 40% higher ritonavir AUC(0-24), and 38% higher ritonavir C12 than achieved in subjects with normal hepatic function receiving the standard fosamprenavir with ritonavir 700 mg / 100 mg twice daily regimen.
Denne patientgruppe bør tage den orale suspension uden mad og på tom mave. 
In this patient population, the oral suspension should be taken without food and on an empty stomach.
Andel med hiv-1-RNA < 50 kopier/ml 
Proportion with HIV-1 RNA < 50 copies/ml
Hos 5 børn i alderen 6 til 24 måneder, der blev behandlet med 45 mg fosamprenavir/kg og 7 mg ritonavir/kg 2 gange daglig, blev det påvist, at på trods af en 5-fold stigning i doser af fosamprenavir og ritonavir, var AUC(0-) for amprenavir i plasma cirka 48 % lavere, Cmax 26 % lavere og C 29 % lavere hos børnene. 
Compared to the historical adult population receiving fosamprenavir with ritonavir 700 mg / 100 mg twice daily, a subset of five pediatric subjects ages 6 to < 24-months receiving fosamprenavir / ritonavir 45/7 mg/kg twice daily demonstrated that despite an approximate 5-fold increase in fosamprenavir and ritonavir doses on a mg/kg basis, plasma amprenavir AUC(0-τ) was approximately 48 % lower, Cmax 26 % lower, and Cτ 29 % lower in the paediatric subjects.
Niveauet af amprenavir og ritonavir kan stige ved seponering af perikon. 
Amprenavir and ritonavir levels may increase on stopping St John's wort.
300 mg én gang daglig 
300 mg once daily
• hovedpine, svimmelhed 
• Headache, feeling dizzy
Bemærk, at samtidig administration af Telzir med lavdosis ritonavir og sildenafil til behandling af pulmonal arteriel hypertension er kontraindiceret (se pkt. 
Note that coadministration of Telzir with low dose ritonavir with sildenafil used for the treatment of pulmonary arterial hypertension is contraindicated (see section
(Kombineret CYP3A4induktion/hæmning) 
(Mixed CYP3A4 induction/inhibition)
Paritaprevir (formuleret sammen med ritonavir og ombitasvir og administreret samtidig med dasabuvir) 
ritonavir and ombitasvir other HIV protease inhibitors and co-administered with and paritaprevir/ritonavir/ dasabuvir)
BENZODIAZEPINER 
BENZODIAZEPINES Midazolam
Naturlægemidler indeholdende perikon må ikke anvendes sammen med Telzir (se pkt. 
Herbal preparations containing St John's wort must not be combined with Telzir (see section 4.3).
ETIKET TIL BEHOLDER TIL TABLETTER 
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING BOTTLE LABEL FOR TABLETS
Studiet er designet til at evaluere farmakokinetikken, sikkerheden, tolerancen og den antivirale aktivitet af fosamprenavir med og uden ritonavir hos børn i alderen 4 uger til 2 år. 
APV20002 is a 48 week, Phase II, open label study designed to evaluate the pharmacokinetics, safety, tolerability and antiviral activity of fosamprenavir with and without ritonavir in paediatric subjects 4 weeks to < 2 years of age.
Amprenavir: Cmax  13 %* Amprenavir: AUC  26 %* Amprenavir: Cmin  42 %* * sammenlignet med fosamprenavir / ritonavir 700 mg/100 mg 2 gange daglig 
Amprenavir: Cmax ↓ 13%* Amprenavir: AUC ↓ 26%* Amprenavir: Cmin ↓ 42 %* * compared to fosamprenavir / ritonavir 700 mg/100 mg twice daily
400 mg 2 gange daglig 
400 mg twice daily
LPV/RTV 2 gange daglig (n=103) 
LPV/RTV BID (N=103)
Andel med hiv-1-RNA < 400 kopier/ml 
Proportion with HIV-1 RNA < 400 copies/ml
Børn kan tage voksendosis, én 700 mg Telzir tablet 2 gange daglig (sammen med 100 mg ritonavir 2 gange daglig), hvis de vejer mindst 39 kg og kan sluge tabletterne hele. 
Children can take the adult dose of one 700 mg Telzir tablet twice daily (with ritonavir 100 mg twice daily) if they weigh at least 39 kg and can swallow the tablets whole.
Alder Kropsvægt Telzir dosis (2 GANGE DAGLIG) 
Telzir dose (TWICE DAILY)
Efavirenz 600 mg én gang daglig 
Efavirenz 600 mg once daily
Proteasehæmmere: Ifølge nuværende retningslinjer frarådes kombinationsbehandling med flere proteasehæmmere. 
According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended.
Paroxetin: Cmax  51 % Paroxetin: AUC 55 % 
Paroxetine: Cmax ↓ 51% Paroxetine: AUC ↓ 55%
Rifampicin 600 mg én gang daglig 
Rifampicin 600 mg once daily
Tag Telzir så længe som lægen har anbefalet. 
Don't stop Telzir without advice Take Telzir for as long as your doctor recommends.
Lægemidler efter terapeutisk område 
Drugs by Therapeutic Area Interaction
Cmax 51 % (-75 % til -3 %) AUC 55 % (-76 % til -16 %) Cmin 36 % (-57 % til -3 %) 
AUC ↓ 55% (-76%; -16%) Cmin ↓ 36 % (-57%; -3%)
LPV/RTV - lopinavir / ritonavir. 
Lopinavir / ritonavir
Methadon ≤ 200 mg én gang daglig 
≤ 200 mg once daily
I et randomiseret åbent studie (APV30003) med proteasehæmmer-erfarne patienter, som havde virologisk svigt (< 2 PI'er) viste kombinationen med fosamprenavir og ritonavir (700/100 mg 2 gange daglig eller 1.400/200 mg én gang daglig) ikke non-inferioritet over for lopinavir/ritonavir med hensyn til viral suppression målt ved det gennemsnitlige areal under kurven minus baseline (AAUCMB) for plasma hiv-1-RNA over 48 uger (det primære endepunkt). 
In a randomised open-label study (APV30003) in protease inhibitor experienced patients with virological failure (less than or equal to two PIs) the fosamprenavir with ritonavir combination (700 / 100 mg twice daily or 1400 / 200 mg once daily) did not demonstrate non-inferiority to lopinavir / ritonavir with regard to viral suppression as measured by the average area under the curve minus baseline (AAUCMB) for plasma HIV-1 RNA over 48 weeks (the primary end point).
De filmovertrukne tabletter er lyserøde, kapselformede og bikonvekse. 
Pink film coated, capsule shaped, biconvex tablets, marked with GXLL7 on one side.
Amprenavir Cmax  Amprenavir AUC  Amprenavir Cmin (C12h)  (Forhøjet gastrisk pH) 
Amprenavir Cmax ↔ Amprenavir AUC ↔ Amprenavir Cmin (C12h) ↔
Ovennævnte studier viste samme bivirkningsprofil og samme kliniske laboratorieværdier som tidligere studier af hiv-1-inficerede personer med normal leverfunktion. 
Fosamprenavir with ritonavir was generally well-tolerated in subjects with mild, moderate, or severe hepatic impairment, and these regimens had similar adverse event and clinical laboratory profiles as previous studies of HIV-1 infected subjects with normal hepatic function.
Hold fast om flasken og sæt plastikadaptoren i flaskehalsen. 
Push the plastic adapter into the neck of the bottle, while holding the bottle firmly.
Patienter (%) med plasma-hiv1-RNA < 50 kopier/ml 
Subjects (%) with plasma HIV-1 RNA <50 copies/ml
YDRE KARTON TIL TABLETTER 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON FOR TABLETS
: + 33 (0)1 39 17 6969 Infomed@viivhealthcare.com 
ViiV Healthcare SAS Tél: + 33 (0)1 39 17 6969 Infomed@viivhealthcare.com
Hos personer med svært nedsat leverfunktion (Child-Pugh score på 10-13) medførte en reduceret dosis af fosamprenavir på 300 mg 2 gange daglig i kombination med 100 mg ritonavir reduceret til én gang daglig en 19 % lavere plasma-Cmax, 23 % lavere plasma-AUC(0-12) og 38 % lavere plasma-C12værdier for amprenavir end hos personer med normal leverfunktion, som fik standardbehandlingen 700 mg fosamprenavir i kombination med 100 mg ritonavir 2 gange daglig. 
In subjects with severe hepatic impairment (Child-Pugh score of 10-13), a reduced dose of fosamprenavir 300 mg twice daily with a reduced dosing frequency of ritonavir 100 mg once daily delivered 19% lower plasma amprenavir Cmax, 23% lower AUC(0-12), and 38% lower C12 values, but similar unbound plasma amprenavir C12 values than achieved in subjects with normal hepatic function receiving the standard fosamprenavir with ritonavir 700 mg / 100 mg twice daily regimen.
Signifikant nedsat eksposition og Cmin er observeret for både amprenavir og raltegravir (især ved samtidig fødeindtagelse), hvilket kan medføre virologisk svigt hos nogle patienter. 
amprenavir and raltegravir (especially in fed conditions) may result in virological
10. Sprøjten må ikke efterlades i flasken efter brug. 
Do not leave the syringe in the bottle.
Til voksne med moderat nedsat leverfunktion (Child-Pugh Score: 7-9) er den anbefalede dosis 450 mg fosamprenavir (f.eks. 9 ml Telzir oral suspension) 2 gange daglig i kombination med 100 mg ritonavir en gang daglig. 
For adults with moderate hepatic impairment (Child-Pugh score: 7-9) the recommended dose is 450 mg fosamprenavir (i.e. 9 ml Telzir oral suspension) twice daily with 100 mg ritonavir once daily.
Rifabutin 150 mg hver anden dag 
150 mg every other day
Hvis du holder op med at tage Telzir 
If you take too much Telzir
Voksne patienter bør tage fosamprenavir oral suspension uden mad og på tom mave. 
For adult patients the fosamprenavir oral suspension should be taken without food and on an empty stomach.
LPV/RTV 400 mg/100 mg 2 gange daglig (n=91) 
LPV/RTV 400 mg/100 mg BID (n=91)
Patienter (%) med plasma-hiv1-RNA < 400 kopier/ml 
Subjects (%) with plasma HIV-1 RNA <400 copies/ml
HMG-COAREDUKTASEHÆMMERE 
HMG-COA REDUCTASE INHIBITORS
• Øvrige indholdsstoffer: hypromellose, sucralose, polysorbat 80, calciumchloriddihydrat, syntetisk grape-tyggegummismagsstof, naturligt pebermyntesmagsstof, renset vand, propylenglycol, methylparahydroxybenzoat (E218) og propylparahydroxybenzoat (E216). 
• The other ingredients are: hypromellose, sucralose, polysorbate 80, calcium chloride dihydrate,
Hver ml af suspensionen indeholder 50 mg fosamprenavir som fosamprenavircalciumsalt (svarende til ca. 43 mg amprenavir). 
Each ml of suspension contains 50 mg of fosamprenavir as fosamprenavir calcium salt (equivalent to approximately 43 mg of amprenavir).
Lopinavir / ritonavir 400 mg/100 mg 2 gange daglig 
400 mg/100 mg twice daily
Atazanavir: Cmax  24 %* Atazanavir: AUC 22 %* Atazanavir: Cmin* *sammenlignet med atazanavir/ ritonavir 300 mg/ 100 mg én gang daglig 
Atazanavir: Cmax ↓ 24%* Atazanavir: AUC ↓ 22%* Atazanavir: Cmin↔* *compared to atazanavir/ ritonavir 300 mg/ 100 mg once daily
Baseline-hiv-1-RNA < 100.000 kopier/ml 
All Subjects Baseline HIV-1 RNA < 100,000 copies/ml
Atorvastatindoser op til 20 mg/dag kan administreres. 
Doses of atorvastatin no greater than 20 mg/day should be administered, with careful monitoring for atorvastatin toxicity.
Česká republika GlaxoSmithKline s.r.o. 
GlaxoSmithKline s.r.o.
Hver tablet indeholder 700 mg fosamprenavir som fosamprenavircalcium (svarende til cirka 600 mg amprenavir). 
Each tablet contains 700 mg of fosamprenavir as fosamprenavir calcium (equivalent to approximately 600 mg amprenavir).
Den sædvanlige dosis er én 700 mg Telzir tablet 2 gange daglig sammen med 100 mg ritonavir 2 gange daglig. 
Adults The recommended dose is one 700 mg Telzir tablet twice daily with 100 mg ritonavir twice daily.
LPV/RTV 400 mg/100 mg 2 gange daglig (n = 444) 
LPV/RTV 400 mg/100 mg BID (n=444)
43 patienter mødte studiedefinerede virologiske fejlkriterier gennem 48 uger i APV29005 og op til 108 uger i APV20003. 
In the paediatric studies APV20003 and APV29005, 77 PI-experienced patients were treated with fosamprenavir / ritonavir-based regimens and 43 patients met study-defined virologic failure criteria through 48 weeks in APV29005 and up to 108 weeks in APV20003.
Hvis du har en moderat leversygdom, er dosis 9 ml Telzir oral suspension (450 mg fosamprenavir) 2 gange daglig med 100 mg ritonavir kun én gang daglig. 
If you have moderate liver disease the dose is 9 ml Telzir oral suspension (450 mg fosamprenavir) twice daily with 100 mg ritonavir only once daily.
< 25 kg Ingen doseringsanbefalinger 
Oral suspension should be taken with food <25 kg No dosing recommendations
Voksne bør tage Telzir oral suspension uden samtidig indtagelse af mad og på tom mave. 
Adults should take Telzir oral suspension without food and on an empty stomach.
I forbindelse med studier af voksne patienter, som fik behandling med PI'er, observeredes følgende mutationer hos de patienter, der fik virologisk svigt: L10F/I/V, V11I, I13V, K20R, V32I, L33F, E34Q, M36I, M46I/L, I47V, G48V, I50V, I54L/M/T/V, Q58E, D60E, I62V, A71V, V77I, V82A/I, I84V, I85V, L90M og I93L/M. 
In the studies of PI-experienced adult patients, PRO30017 (amprenavir 600 mg / ritonavir 100 mg twice daily in sub-study A and B with 80 and 37 patients respectively), the following mutations emerged in patients with virological failure: L10F/I/V, V11I, I13V, K20R, V32I, L33F, E34Q, M36I, M46I/L, I47V, G48V, I50V, I54L/M/T/V, Q58E, D60E, I62V, A71V, V77I, V82A/I, I84V, I85V, L90M and I93L/M.
Amiodaron:  forventet Bepridil:  forventet Quinidin:  forventet (FPV/RTV hæmmer CYP3A4) 
Amiodarone: ↑ expected Bepridil: ↑ expected Quinidine: ↑ expected (CYP3A4 inhibition by FPV/RTV)
Hvis du har en mild leversygdom, er den sædvanlige dosis én Telzir tablet (700 mg) 2 gange daglig med 100 mg ritonavir kun én gang daglig. 
If you have mild liver disease, the dose is one Telzir tablet (700 mg) twice daily with 100 mg ritonavir only once daily.